Drug Trial Radar · NCT04469621
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jul 17, 2020
Primary completion
Oct 23, 2020
Study completion Oct 23, 2020
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019 (COVID-19) Secondary Objectives: * To evaluate the time to onset of effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by CRP levels * To evaluate the time to onset of effect of SAR443122 relative to the control arm on oxygenation status * To evaluate the effect of SAR443122 relative to the control arm on oxygenation status * To evaluate the effect of SAR443122 relative to the control arm on total duration of supplemental oxygen requirement * To evaluate the effect of SAR443122 relative to the control arm on length of ventilator support needed * To evaluate the effect of SAR443122 relative to the control arm on laboratory markers of severe COVID-19 * To evaluate the effect of SAR443122 relative to the control arm on mortality * To evaluate the effect of SAR443122 relative to the control arm on need for thrombolytic therapy * To evaluate the effect of SAR443122 relative to the control arm on need for vasopressor treatment * To evaluate the safety of SAR443122 as compared to the control arm up to End of Study * To evaluate the effect of SAR443122 relative to the control arm on total duration without high flow supplemental oxygen requirements
Conditions
- Corona Virus Infection
Interventions
SAR443122Drug
Pharmaceutical form:capsule Route of administration: oral
PlaceboDrug
Pharmaceutical form:capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change from baseline in CRP levelTime frame: Day 7
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Investigational Site Number 0320001
Caba, Argentina
Investigational Site Number 0760003
Porto Alegre, Brazil
Investigational Site Number 0760001
São José do Rio Preto, Brazil
Investigational Site Number 0760002
São Paulo, Brazil
Investigational Site Number 1520001
Santiago, Chile
Investigational Site Number 1520003
Santiago, Chile
Investigational Site Number 1520002
Talca, Chile
Investigational Site Number 4840001
Monterrey, Mexico
Investigational Site Number 6430001
Moscow, Russia
Investigational Site Number 6430002
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.